Amneal Pharmaceuticals (NASDAQ:AMRX) Receives "Overweight" Rating from JPMorgan Chase & Co.

Key Points

• JPMorgan reaffirmed an “overweight” rating on Amneal Pharmaceuticals and set a $22 price target, implying 22.46% upside from the reported $17.96 share price.
• Amneal’s latest quarterly results exceeded expectations, with earnings per share of $0.30 versus the $0.24 consensus and revenue of $796.2 million. Analysts collectively rate the stock “Buy,” with an average target price of $19.
• Several company insiders sold shares recently, including a director and an executive vice president; insiders sold $7.2 million worth of stock in the last quarter while retaining 17.3% ownership.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research report issued on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 22.46% from the stock's current price.

AMRX has been the topic of several other reports. The Goldman Sachs Group reissued a "buy" rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 20th. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. UBS Group lifted their price target on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Finally, Zacks Research upgraded Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $19.00.

Amneal Pharmaceuticals Stock Performance

AMRX stock traded up $0.04 during midday trading on Wednesday, reaching $17.96. 148,459 shares of the company were exchanged, compared to its average volume of 2,126,266. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The business has a 50-day moving average price of $17.59 and a two-hundred day moving average price of $14.79. Amneal Pharmaceuticals has a one year low of $9.20 and a one year high of $19.26. The firm has a market capitalization of $5.74 billion, a price-to-earnings ratio of 36.70 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts forecast that Amneal Pharmaceuticals will post 0.94 EPS for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares in the company, valued at approximately $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nikita Shah sold 146,403 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the sale, the executive vice president owned 253,390 shares of the company's stock, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock valued at $7,216,567 in the last quarter. Company insiders own 17.30% of the company's stock.

Institutional Trading of Amneal Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP increased its position in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company's stock worth $123,473,000 after purchasing an additional 624,609 shares during the period. Dimensional Fund Advisors LP grew its stake in Amneal Pharmaceuticals by 1.5% during the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company's stock worth $70,723,000 after buying an additional 81,546 shares in the last quarter. Morgan Stanley grew its stake in Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company's stock worth $60,708,000 after buying an additional 1,315,018 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company's stock valued at $35,333,000 after buying an additional 558,877 shares during the period. Finally, State Street Corp raised its position in shares of Amneal Pharmaceuticals by 3.4% in the 4th quarter. State Street Corp now owns 4,110,410 shares of the company's stock valued at $51,791,000 after buying an additional 136,662 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source